期刊
CANCERS
卷 13, 期 12, 页码 -出版社
MDPI
DOI: 10.3390/cancers13123026
关键词
hepatocellular carcinoma; MAPK; ERK signaling; animal models; targeted therapies
类别
资金
- National Research Foundation of Korea (NRF) - Korean government (MSIT) [2021R1C1C2006182, 2019R1A2C2009518]
- Kyung Hee University [KHU-20201758]
- National Research Foundation of Korea [2019R1A2C2009518, 2021R1C1C2006182] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
The MAPK/ERK signaling pathway is frequently activated in liver cancer, with alternative mechanisms other than genetic mutations driving its activation. Recent studies have focused on understanding the cellular and molecular mechanisms involved in the activation of the MAPK/ERK signaling pathway in HCC, suggesting potential therapeutic strategies targeting this pathway.
Simple Summary The mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway is frequently activated in liver cancer, which is one of the most lethal cancers in humans. In addition to genetic mutation leading to persistent activation of effector molecules in the MAPK/ERK signaling cascade, there are alternative means by which the MAPK/ERK signaling pathway is activated in cancer. In this review, we will introduce the diverse modulators regulating the MAPK/ERK signaling pathway and consider the possibility of targeting the effectors and regulators in order to suppress the pro-tumorigenic MAPK/ERK signaling pathway, especially in liver cancer. Hepatocellular carcinoma (HCC) is a major health concern worldwide, and its incidence is increasing steadily. Recently, the MAPK/ERK signaling pathway in HCC has gained renewed attention from basic and clinical researchers. The MAPK/ERK signaling pathway is activated in more than 50% of human HCC cases; however, activating mutations in RAS and RAF genes are rarely found in HCC, which are major genetic events leading to the activation of the MAPK/ERK signaling pathway in other cancers. This suggests that there is an alternative mechanism behind the activation of the signaling pathway in HCC. Here, we will review recent advances in understanding the cellular and molecular mechanisms involved in the activation of the MAPK/ERK signaling pathway and discuss potential therapeutic strategies targeting the signaling pathway in the context of HCC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据